The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
METER study: Real-world treatment patterns in patients with MF
|
Prior to the approval of ruxolitinib, HU was the most used 1L therapy for patients with MF.1 The impact of ruxolitinib and other JAKi approvals on the utilization of therapies remains unclear, and factors influencing changes in MF treatment choices in real-world settings are poorly understood.1 The multi-country, noninterventional, retrospective chart review METER study (NCT05444972) assessed treatment patterns, clinical outcomes, and healthcare resource utilization in patients with MF.1 Data were collected from 997 adult patients with primary or secondary MF from 66 sites across 14 countries between August 23, 2022, and November 14, 2023. Results were published in Blood Advances by Gupta, et al.1 |
| Key learnings |
| Ruxolitinib was the most common 1L (49.0%) and 2L (61.9%) treatment for MF, surpassing HU (1L, 40.2%; 2L, 28.4%). ∼50% of patients discontinued or switched treatments due to inadequate response (27.3%), disease progression (17.8%), or toxicity (11.5%). |
| The cumulative incidence of allo-HSCT was 2.2% at 24 weeks, increasing to 11.0% at 156 weeks in patients aged ≤70 years. |
|
Median OS for all patients was 79.1 months and was reduced with ruxolitinib (1L, 77.6 months; 2L+, 72.6 months) vs other therapies (142.3 months); possibly attributable to less aggressive disease. Risk factors such as age ≥65 years, male sex, high-risk classification, BMF ≥2, and TD were associated with reduced survival. |
| Among patients with ≥1 corresponding event, median hospital and ICU stay durations were 16 days and 5 days respectively, with a median of 12 transfusion events; highlighting persistent unmet needs in this patient population. |
Abbreviations: 1L, first-line; 2L, second-line; allo-HSCT, allogeneic hematopoietic stem cell transplantation; BMF, bone marrow fibrosis; HU, hydroxyurea; ICU, intensive care unit; JAKi, Janus kinase inhibitor; MF, myelofibrosis; OS, overall survival; TD, transfusion dependency.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?
